MALLINCKRODT IRELAND
SpecialtyMALLINCKRODT IRELAND is a specialty pharmaceutical company focused on Respiratory, Cardiovascular, Immunology. Key products include TERLIVAZ.
FDA Novel Drug Designations
(2022)See 1 novel approval →
MALLINCKRODT IRELAND at a Glance
- Fast trial execution (13 months median completion)
MALLINCKRODT IRELAND's Key Drugs
MALLINCKRODT IRELAND's core commercial portfolio centers on TERLIVAZ, spanning Respiratory and Cardiovascular — its most strategically important drugs approved in the last 15 years.
MALLINCKRODT IRELAND's Recent FDA Approvals
New NDA/BLA approvals for MALLINCKRODT IRELAND over the last two years — novel drugs only, excluding generics and label supplements.
MALLINCKRODT IRELAND's Therapeutic Areas
MALLINCKRODT IRELAND's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Cardiovascular, across 0 biologic and 3 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MALLINCKRODT IRELAND's Top Competitors
MALLINCKRODT IRELAND's closest competitors by therapeutic-area and drug-target overlap include Novartis, AstraZeneca, and Takeda. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MALLINCKRODT IRELAND Pipeline Snapshot
MALLINCKRODT IRELAND has 15 active clinical programs from ClinicalTrials.gov — 8 Phase 3, 2 Phase 2 and 5 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • TERLIVAZ leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Respiratory pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 15/18 completed
- • Speed: 13 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 1952-04-29
- Latest
- 2026-06-10
- Applications
- 3
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges